The TP53 mutation and TP53 related pathways could serve as driver mutations in bladder cancer, which promotes disease progression and influences cancer prognosis and therapeutic strategy (Cazier et al., 2014; Lang et al., 2004). The gene discussed is TP53; the disease is urinary bladder carcinoma.